Medicare AdvantagePrior AuthMedium impact
Alvaiz™ (eltrombopag choline) tablet (Revised)
Humana·Hematology, Oncology, Gastroenterology +1 more·Medicare Advantage
Effective date
Aug 28, 2024
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Alvaiz (eltrombopag choline) tablets for Medicare Advantage plans, covering treatment of chronic ITP, hepatitis C-related thrombocytopenia, and severe aplastic anemia. All prescriptions require prior authorization with specific clinical criteria including platelet counts and previous treatment history.
Action Required
Immediately: Billing team must ensure all Alvaiz (eltrombopag choline) tablet prescriptions for Medicare Advantage patients have prior authorization before dispensing. Providers must document diagnosis (ITP, hepatitis C with thrombocytopenia, or aplastic anemia), platelet counts, and previous treatment responses. Update pharmacy systems to flag this medication for PA requirements. Claims will be denied without proper authorization.